Concurrent Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.4M Buy
42,833
+2,418
+6% +$2.45M 0.43% 42
2025
Q4
$43.4M Buy
40,415
+11,463
+40% +$11M 0.49% 33
2025
Q3
$22.1M Sell
28,952
-438
-1% -$326K 0.38% 54
2025
Q2
$22.9M Buy
29,390
+1,715
+6% +$1.33M 0.44% 44
2025
Q1
$22.9M Buy
27,675
+3,255
+13% +$2.71M 0.55% 31
2024
Q4
$18.9M Buy
24,420
+611
+3% +$506K 0.51% 38
2024
Q3
$21.1M Buy
23,809
+695
+3% +$625K 0.62% 28
2024
Q2
$20.9M Buy
23,114
+7,842
+51% +$6.27M 0.69% 25
2024
Q1
$11.9M Buy
15,272
+433
+3% +$308K 0.48% 48
2023
Q4
$8.65M Buy
+14,839
New +$8.66M 0.41% 57

Other funds holding LLY

Concurrent Investment Advisors's LLY Position: Q1 2026 in Review

Concurrent Investment Advisors increased its Eli Lilly (LLY) stake by 6% in Q1 2026, buying an estimated $2.45M and bringing the position to 42,833 shares worth $39.4M. The position accounts for 0.43% of the portfolio, ranked #42.

Concurrent Investment Advisors first reported a position in LLY in Q4 2023 and has held it in 10 quarters since. The position peaked at $43.4M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Concurrent Investment Advisors held 42,833 shares of Eli Lilly worth $39.4M as of Q1 2026.
  • Concurrent Investment Advisors bought 2,418 Eli Lilly shares in Q1 2026, an estimated $2.45M.
  • Eli Lilly made up 0.43% of Concurrent Investment Advisors's portfolio in Q1 2026, its #42 holding.
  • Concurrent Investment Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 10 quarters since.
  • Concurrent Investment Advisors's Eli Lilly position peaked at $43.4M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.